

IQVIA's Diabetes and Obesity Health Insights Dashboard

Monitoring drug treatment trends for diabetes and obesity in Canada

Diabetes and obesity are public health issues of unprecedented magnitude in North America. These two conditions, often interconnected, affect millions of people and represent a major cause of morbidity and mortality.

What reliable information can government, healthcare authorities, healthcare providers, and not-for-profit (NGO) organizations access to help them see trends and make timely decisions?

Introducing IQVIA's Diabetes and Obesity Health Insights Dashboard

Available at no cost to health researchers, this dynamic, insight-rich dashboard helps stakeholders monitor and understand drug treatment trends for diabetes and obesity in Canada.

The dashboard contains data from community pharmacies and IQVIA's unparallelled prescription medication data sets and was developed in collaboration with medical and pharmaceutical professionals.



The evidence you need to help make the right decisions

In our mission at IQVIA to enhance healthcare, we offer stakeholders reliable, easily accessible, and up-to-date data. This evidence helps governments, healthcare authorities, healthcare providers and NGOs focus efforts on areas with rising diabetes prevalence, enabling the development of targeted strategies to raise awareness and educate professionals.

Five years of data

Fully anonymized prescription data for antidiabetic drugs and obesity treatment dispensed by a panel of community pharmacies over a five-year period (2019 to 2023) highlighting variations at the demographic level.

Dynamic data

Regularly updated data to help track regional variations in prevalence and prescribing to assess the effectiveness of programs.



IQVIA data

Benefit from other IQVIA data services such as prescription monitoring, longitudinal and prescriber-level data.

Complete geographic coverage

National, provincial, and regional prescription data to identify current and emerging trends that impact providers, patients, governments, and regulators. Includes data from health regions including 26 in Ontario and 15 in Quebec.



Representative analysis

We receive information on ~80% of all prescriptions dispensed in Canada (new Rx and refills). We use algorithms to estimate the remaining drugs dispensed.



Population, age, and gender data to calculate prevalence.